Ami Organics IPO notes โ๏ธ
Supplies Raw materials (Intermediates) to API players (7% of revenues from Laurus Labs for example)
Hit the 'retweet' & help us educate more investors
A Thread ๐งต๐
1/ Basics about the IPO.
Raising 200crs of Fresh Issue (& OFS of 370crs): will be used for repayment of debt & WC
MCap at 2200crs: EV/S of 6 & EV/EBITDA of 26 (stretched for an unknown company)
Promoters only hold 41% after the IPO
2/ An Pharma intermediates player that sells to API players focusing on high-growth therapeutics.
Caters to 150 customers (incl. Laurus, Cadila & MNC players, etc) | 50% exports
3/ R&D Expertise: Market leader across many intermediates | 66 R&D Personnel | 8 Process Patents | 1-2% of rev
High Entry Barriers due to the complex chemistries
The capacity of 6060 MTPA (3600MTPA recently through inorganic): old plant of 2460 MTPA at 60% utilisation
4/ Breakup of the rev ๐
Could be helpful in tracking how the offtake of other companies are; for ex: they supply intermediates of Dolutegravir to Laurus Labs.
5/ 5 customers account for 44% of the rev: Concentration risk; any change in end product offtake will have reverberations into their P&L.
GMs have increased from 33% to 45% in 3yrs: Might not be sustainable
6/ Acquired the incremental 3600 MTPA capacity for just 93crs; ability to scale up with higher value products is a key trackable.
7/ Financials:
High Working capital requirements: weak cash flow conversion | High Asset Turnover ensures a good return on capital
Revenue growth might sustain as the new plants ramp up, although margins look to be on the higher side (Gross margins look subnormal)
8/ Risks:
- Unlisted group company into APIs which wasn't mentioned in the IPO prospectus; check out the tweets below by @arpit971 & @tusharbohra
- Any adverse USFDA reaction
- Not clear if they can pass on the RM price increases
9/
- Operations are dependent on the ability to collaborate & innovate; a key trackable
- Newly acquired plants (60% of total capacity) from Gujarat Organics might not yield effective results.
- Product concentration risks: 40-45% of rev from 2 products ๐
10/
Outlook:
Better be cautious rather than aggressive in betting on a new company (not to forget, in a sector which is currently valued as if nothing can go wrong) with so many unknowns; even the valuations are not in our favour.
Comparison with the peers ๐
End of Thread.
Edit: They have mentioned their group company "Ami Lifesciences" which is into APIs in their RHP.
Share this Scrolly Tale with your friends.
A Scrolly Tale is a new way to read Twitter threads with a more visually immersive experience.
Discover more beautiful Scrolly Tales like this.